Traws Pharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Werner Cautreels
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO
Werner Cautreels (72 yo)
less than a year
Tenure
Dr. Werner Cautreels, Ph.D. serves as Member of Advisory Board at Thuja Capital Management B.V. He also serves as Chief Executive Officer & Director of Traws Pharma, Inc. since April 01, 2024. He has been...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 8.3yrs | US$745.52k | 0.052% € 7.6k | |
| Chief Medical Officer of Oncology | 1.3yrs | US$405.25k | 0% € 0 | |
| Executive Chairman | less than a year | no data | 0.48% € 70.8k | |
| CEO & Director | less than a year | no data | no data | |
| COO & Director | less than a year | no data | 1.66% € 242.0k | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Scientific Officer of Virology | less than a year | no data | no data |
0.7yrs
Average Tenure
66yo
Average Age
Experienced Management: 0T20's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | less than a year | no data | 0.48% € 70.8k | |
| CEO & Director | less than a year | no data | no data | |
| COO & Director | less than a year | no data | 1.66% € 242.0k | |
| Independent Director | 8.6yrs | US$126.72k | 0.00030% € 43.9 | |
| Chairman of Scientific Advisory Board | 8yrs | no data | no data | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | US$118.22k | 0.0045% € 657.8 | |
| Independent Director | less than a year | no data | no data |
2.7yrs
Average Tenure
69yo
Average Age
Experienced Board: 0T20's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 10:51 |
| End of Day Share Price | 2024/09/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Traws Pharma, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Thomas Cooper | Edison Investment Research |
| Etzer Darout | Guggenheim Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |